227 related articles for article (PubMed ID: 31621054)
1. The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.
Muehler A; Kohlhof H; Groeppel M; Vitt D
Drugs R D; 2019 Dec; 19(4):351-366. PubMed ID: 31621054
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Herrlinger KR; Diculescu M; Fellermann K; Hartmann H; Howaldt S; Nikolov R; Petrov A; Reindl W; Otte JM; Stoynov S; Strauch U; Sturm A; Voiosu R; Ammendola A; Dietrich B; Hentsch B; Stange EF
J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
[TBL] [Abstract][Full Text] [Related]
3. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
Muehler A; Peelen E; Kohlhof H; Gröppel M; Vitt D
Mult Scler Relat Disord; 2020 Aug; 43():102129. PubMed ID: 32428844
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects.
Muehler A; Kohlhof H; Groeppel M; Vitt D
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):557-573. PubMed ID: 32361977
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.
Fox RJ; Wiendl H; Wolf C; De Stefano N; Sellner J; Gryb V; Rejdak K; Bozhinov PS; Tomakh N; Skrypchenko I; Muehler AR
Ann Clin Transl Neurol; 2022 Jul; 9(7):977-987. PubMed ID: 35698927
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide in the treatment of rheumatoid arthritis.
Li EK; Tam LS; Tomlinson B
Clin Ther; 2004 Apr; 26(4):447-59. PubMed ID: 15189743
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Nov; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
[TBL] [Abstract][Full Text] [Related]
8. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Cohen S; Schiff M; Weaver A; Fleischmann R; Cannon G; Fox R; Moreland L; Olsen N; Furst D; Caldwell J; Kaine J; Sharp J; Hurley F; Loew-Friedrich I
Arch Intern Med; 1999 Nov; 159(21):2542-50. PubMed ID: 10573044
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
10. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
12. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
14. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
Kremer JM; Genovese MC; Cannon GW; Caldwell JR; Cush JJ; Furst DE; Luggen ME; Keystone E; Weisman MH; Bensen WM; Kaine JL; Ruderman EM; Coleman P; Curtis DL; Kopp EJ; Kantor SM; Waltuck J; Lindsley HB; Markenson JA; Strand V; Crawford B; Fernando I; Simpson K; Bathon JM
Ann Intern Med; 2002 Nov; 137(9):726-33. PubMed ID: 12416946
[TBL] [Abstract][Full Text] [Related]
15. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
17. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
20. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
